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OBJECTIVE: Remote ischemic preconditioning (RIPC) is a phenomenon in which a short period of sub-lethal
ischemia in one organ protects against subsequent bouts of ischemia in another organ. We hypothesized that
RIPC in patients with intermittent claudication would increase muscle tissue resistance to ischemia, thereby
resulting in an increased ability to walk.
METHODS: In a claudication clinic, 52 ambulatory patients who presented with complaints of intermittent
claudication in the lower limbs associated with an absent or reduced arterial pulse in the symptomatic limb and/
or an ankle-brachial index ,0.90 were recruited for this study. The patients were randomly divided into three
groups (A, B and C). All of the patients underwent two tests on a treadmill according to the Gardener protocol.
Group A was tested first without RIPC. Group A was subjected to RIPC prior to the second treadmill test. Group
B was subjected to RIPC prior to the first treadmill test and then was subjected to a treadmill test without RIPC.
In Group C (control group), both treadmill tests were performed without RIPC. The first and second tests were
conducted seven days apart. Brazilian Clinical Trials: RBR-7TF6TM.
RESULTS: Group A showed a significant increase in the initial claudication distance in the second test compared
to the first test.
CONCLUSION: RIPC increased the initial claudication distance in patients with intermittent claudication;
however, RIPC did not affect the total walking distance of the patients.
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& INTRODUCTION
Ischemic preconditioning (IPC) was first described in
1986 by Murry et al. (1) as an increase in cellular resistance
to myocardial ischemia when the heart is exposed to periods
of brief non-lethal ischemia interspersed with reperfusion.
In 1993, Pryzklenk et al. (2) demonstrated that an increase in
cell resistance to ischemia also occurred in other tissues that
were not directly subjected to ischemia. This phenomenon
was named remote ischemic preconditioning (RIPC) (3-18).
Although some authors question whether RIPC actually
occurs (19), many studies have demonstrated the beneficial
effects on myocardial cells after transient ischemia is
encountered by other tissue (20-22). Cells in organs other
than the heart are sensitive to the protective effects that
follow ischemia-reperfusion injury of the myocardial tissue
or other distant tissues (23-26). Based on evidence of RIPC
occurring in other tissues, we predicted that RIPC could
occur in patients with intermittent claudication (IC), thereby
making the muscles more resistant to ischemia and
increasing the ability of these individuals to walk. To test
this hypothesis, we performed gait tests in patients with
claudication with and without prior RIPC and then
compared the initial claudication distance (ICD) and the
total walking distance (TWD).
& METHODS
This study was performed at the Intermittent
Claudication Clinic of the Hospital das Clı´nicas, Faculdade
de Medicina at the Universidade de Sa˜o Paulo after
receiving approval from the local ethics committee. All of
the participants signed informed consent forms prior to
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their enrollment. This study was registered as a clinical trial
in the Brazilian Clinical Trials Registry (trial RBR-7TF6TM).
Between January 2009 and May 2011, 52 consecutive
ambulatory patients complaining of typical intermittent
claudication (IC) in one or both lower limbs that was
associated with an absent or reduced arterial pulse in the
symptomatic limb and/or an ankle-brachial index ,0.90
were recruited for this study. Physical examinations of the
upper limbs revealed normal physiology in all the study
participants.
The patients were randomly divided into three groups (A,
B and C) and underwent two treadmill tests according to the
Gardener protocol. Group A was first tested on a treadmill
without undergoing RIPC, and then Group A was tested on
a treadmill after undergoing RIPC. Group B was first tested
on a treadmill after receiving RIPC, and then Group B was
tested on a treadmill without receiving RIPC. In Group C
(control group), both treadmill tests were conducted with-
out the patient receiving RIPC. The treadmill tests were
conducted seven days apart.
The tests were conducted on a treadmill running at a
fixed speed of 3.2 km/h, and the required effort was
progressively increased (2% increase in the incline every 2
minutes). The initial claudication distance (ICD), which
describes the maximum distance a patient can walk without
experiencing leg pain, and the total walking distance
(TWD), which refers to the distance walked before the
patient could not continue walking, were recorded in each
test.
RIPC was implemented according to a previously
described protocol (22), which is detailed below.
Ninety minutes before exercising on the treadmill, an
inflated cuff was positioned on the non-dominant upper
limb of the participant three times for five minutes each
time. Between each period of inflation, the cuff was deflated
for five minutes.
The participants were advised to avoid consuming the
following substances, which have been suggested to
interfere with the process of ischemic preconditioning
(RIPC), within two hours of the test: cilostazol, sildenafil,
dipyridamole, glibenclamide, aminophylline, nicorandil,
phenylephrine, angiotensin-converting enzyme inhibitors,
angiotensin receptor blocker II, statins and steroids, caffeine
and alcohol.
Considering the experimental nature of this study, the
number of subjects included in each group was calculated
based on sample power, as proposed by J. Eng (41).
Statistical analysis
The statistical analyses were conducted using the Statistic
5.1 software (StatSoft, Inc., Tulsa, OK, USA). The data were
first tested for normality and homogeneity of variance using
the Shapiro-Wilk and Levene tests, respectively.
To compare the general characteristics of the three
experimental groups, we used an analysis of variance
(ANOVA) of one factor for continuous variables and the
chi-squared or Fisher’s exact test for categorical variables.
To compare ICD and TWD between the three experimental
groups, a two factorial ANOVA for repeated measurements
was used considering the group (A, B and C) as an
independent factor and the time (first or second test) as
the repeated factor. When significant effects were observed,
the post-hoc Duncan’s test was used to verify differences.
Data are presented as relative frequencies, means and
standard deviations. For all of the analyses, a significance
level of p,0.05 was assumed.
& RESULTS
A total of 52 patients were analyzed in this study, which
included 38 males and 14 females. General patient char-
acteristics are shown in Table 1. No differences were
observed between the groups regarding age, race, gender,
diabetes prevalence, hypertension prevalence and smoking
history. However, Group C had a higher prevalence of
dyslipidemia relative to the other groups (p= 0.017).
Table 2 shows the effect of RIPC on the walking capacity
of the IC patients. Group A and Group C patients had
higher initial claudication distances (ICDs) in the second test
relative to the first test. However, no differences were found
in Group B. Furthermore, the ICD was greater in Group A
patients when compared with the other groups. Table 2 also
shows that the total walking distance (TWD) was lower in
the first test than in the second test for Group A and Group
B. However, there were no significant differences between
the groups (see Figures 1 and 2).
& DISCUSSION
Initial studies analyzing RIPC used animal models in an
attempt to show the effects of RIPC by comparing the area
of injury in tissues exposed and not exposed to periods of
ischemia-reperfusion induced by ligating the arterial feeder
vessel. Pryzklenk et al. were the first to demonstrate that
small cycles of coronary artery occlusions in dogs protected
the myocardial cells from longer periods of ischemia (2).
Later, the protective effect induced by ischemia could be
transferred to non-preconditioned rabbits that received
whole blood transfusions from rabbits that were subjected
to RIPC (29). Other studies have shown reductions in the
area of myocardial infarction in animals subjected to RIPC
induced by the intermittent occlusion of the femoral, renal
Table 1 - General characteristics of patients with intermittent claudication.
Variables Group A (n=18) Group B (n=16) Group C (n=18) p-value
Age (years) 65.8¡7.9 60.5¡9.5 64.0¡9.9 0.145
Gender (% males) 72.2 69.8 77.8 0.835
Skin color (% whites) 72.2 75.0 77.8 0.929
Risk factors
Diabetes mellitus (%) 23.5 37.5 44.4 0.422
Hypertension (%) 77.8 62.5 94.4 0.074
Dyslipidemia (%) 38.9 25.0 72.2 0.017
History of smoking 94.4 93.8 83.3 0.456
Values are expressed as the mean ¡ standard deviation.
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and mesenteric arteries (30-32). In addition to the cardiac
muscle, other organs and tissues have been shown to
respond to the protective effect of RIPC, including the lungs,
kidneys, liver and skeletal muscle (23,33-35).
Of the few RIPC studies that have been conducted in
human subjects, some have shown that RIPC protects
endothelial function after ischemia-reperfusion injury
(22,36,37), and other studies have shown the protection of
myocardial cells in patients undergoing cardiac operations
(38,39). For patients undergoing segmental hepatectomy,
RIPC before the operation led to reduced liver enzymes
during the immediate postoperative period compared with
patients in whom RIPC was not performed, but no
differences in mortality and morbidity were observed (40).
RIPC may be mediated by humoral factors and/or through
the neurogenic pathway consisting of an early phase that
begins after the completion of preconditioning and persists
for upwards of 4 hours, and a late phase that begins
approximately 24 hours after RIPC and persists for nearly 48
hours. Several humoral factors appear to be involved in
mediating RIPC, including opioids, nitric oxide, adenosine,
catecholamines, bradykinin, heat shock proteins, heme
oxygenase, tumor necrosis factor-alpha, free radicals,
prostaglandins and angiotensin. Organs subjected to ische-
mia have been shown to activate the protein kinase C
intracellular pathway resulting in the nuclear translocation
of nuclear factor kappa beta and the subsequent activation
of nitric oxide synthesis. Common mechanisms involved in
target organs in the early and late stages of RIPC remain
unclear; however, some studies have suggested roles for
mitochondrial KATP channels and neutrophils.
RIPC is of particular interest with respect to peripheral
arterial disease such as intermittent claudication (IC). RIPC
could explain, at least partially, the success of physical
training in treating patients with IC. The mechanism by
which exercise improves the symptoms of vascular-
mediated IC remains poorly understood. Furthermore, the
initial concept that physical activity promotes increased
collateral circulation by stimulating neoangiogenesis lacks
definitive evidence (27). Current theories have sought to
associate the improvement in walking distance to changes
in muscle metabolism induced by exercise (28). Repeated
ischemia-reperfusion events caused by physical training
could be the stimulus for intracellular biochemical changes
leading to a more effective use of oxygen by the muscle and
an improvement in endothelial function. This theory is
based on the concept of RIPC.
In patients with claudication, a major goal of treatment is
to improve the quality of life by increasing the ICD and
TWD. Therefore, these parameters were used in our study
Table 2 - Effect of remote ischemic preconditioning (RIPC) on initial claudication distance (ICD) and total walking
distance (TWD) in the three experimental groups.
First test Second test Group effect Moment effect Interaction effect
ICD (m)
Group A (n=18) 164¡79 197¡85* 0.518 0.039 0.045
Group B (n =16) 147¡112 134¡91{
Group C (n =18) 143¡114 173 ¡ 135*{
TWD (m)
Group A (n=18) 352¡173 435 ¡ 182* 0.692 ,0.001 0.595
Group B (n =16) 309¡168 364 ¡ 218*
Group C (n =18) 308¡214 421 ¡ 279*
Values are expressed as the mean ¡ standard deviation. *Significant difference compared with the first test; {Different from Group A (p,0.05).
Group effect indicates whether a statistically significant difference exists between the groups (A, B and C).
Moment effect indicates whether a statistically significant intra-patient difference exists between the results from the first and second treadmill tests
(days 1 and 7).
The interaction effect indicates whether a statistically significant difference exists in both the group and moment effects.
Figure 1 - Effect of remote ischemic preconditioning (RIPC) on
the initial claudication distance (ICD).
Figure 2 - Effect of remote ischemic preconditioning (RIPC) on
the total walking distance (TWD).
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to evaluate patient responses to RIPC treatment using each
patient as his/her own control. We compared the distances
walked in each treadmill test with and without RIPC.
Because many patients were not used to walking on a
treadmill, some patients may have been able to walk a
greater distance in the second test after becoming more
familiar with walking on the treadmill relative to the first
test. Therefore, we divided the patients into two groups that
differed in RIPC administration and a control group.
In this study, a significant increase in the ICD was
observed in the second treadmill test for Group A and
Group C, and this increase was greater in Group A
compared to Group C. All of the groups showed a
statistically significant increase in the second treadmill test
for the TWD regardless of RIPC treatment. These findings
suggested that two factors contributed to an increase in
walking distance: RIPC and an increase in patient famil-
iarity with treadmill use. Thus, Group A averaged a
significantly higher ICD in the second week when com-
pared to the first week. However, in Group B, the factors
responsible for increasing the distance walked (RIPC and
treadmill familiarization) appeared to antagonize the effect
of each other because of the timing of the treadmill test. If
RIPC had no beneficial effect on treadmill performance,
then the distance walked in the second test should increase
regardless of whether RIPC was administered prior to the
first test or the second test; however, this was not the case in
our study.
The fact that the TWD did not change upon RIPC
treatment is most likely caused by ischemic conditioning,
which is expected in claudication patients, as ischemia is the
cause of the symptoms of claudication. However, as RIPC
activates several signaling pathways, we believe that path-
ways that are not activated or that are partially activated
may become fully activated after RIPC, such as the opioid
pathway. We suspect that the activation of other signaling
pathways by RIPC could explain why the ICD increased, as
opioids may increase tolerance to pain.
Future studies should attempt to identify the biochemical
agents responsible for the benefits of RIPC in claudication
patients, which could allow for the exogenous administra-
tion of these factors to claudication patients bringing relief
of symptoms. However, prior to the developing therapeu-
tics for claudication patients, evidence confirming the
benefits of RIPC in these individuals is necessary, which
was the main objective of our study.
Because RIPC did not change the TWD, RIPC did not
appear to be useful for claudication treatment, and conven-
tional treatments involving exercise training (walking and/
or exercise with load), risk factor control, smoking cessation
and drug therapy with aspirin and simvastatin remain the
best therapeutic option. However, as patients with claudica-
tion are constantly exposed to ischemic conditioning in the
lower limbs and because the lower limbs account for a large
proportion of the skeletal muscle, claudication patients are
an ideal model to research signaling pathways involved
with the RIPC effect as well as the triggers of RIPC. RIPC
research can lead to the development of therapeutics that
could increase cellular resistance to ischemia in patients
subjected to acute ischemia, such as trauma patients or
major surgery patients.
Additional studies are needed to clarify the effects of
RIPC and the mechanism of action through which tissues
that are not directly subjected to ischemia benefit upon
subsequent ischemic insults.
RIPC increases the initial claudication distance in patients
with intermittent claudication. However, RIC does not affect
the total walking distance of claudication patients.
& ACKNOWLEDGMENTS
Fundac¸a˜o de Amparo a` Pesquisa do Estado de Sa˜o Paulo (Fapesp); grant
numbers: 2008/03203-1.
& AUTHOR CONTRIBUTIONS
Saes GF and Zerati AE were responsible for the study concept and design,
patient recruitment, data collection and manuscript writing. Wolosker N
was responsible for the study concept and design, patient recruitment and
writing of the manuscript. Ragazzo L was responsible for patient
recruitment, data collection and final approval. Rosoky RM was
responsible for the study concept and design, and manuscript writing.
Ritti-Dias RM, Cucato GG and Chehuen M were responsible for
cardiovascular screening and final approval. Farah B was responsible for
statistical expertise and final approval. Puech-Lea˜o P provided medical
support during the study and approved the final version of the manuscript.
& REFERENCES
1. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a
delay of lethal cell injury in ischemic myocardium. Circulation.
1986;74(5):1124-36, http://dx.doi.org/10.1161/01.CIR.74.5.1124.
2. Przyklenk K, Bauer B, Ovize M, Kloner RA, Whittaker P. Regional
ischemic ‘preconditioning’ protects remote virgin myocardium from
subsequent sustained coronary occlusion. Circulation. 1993;87(3):893-9,
http://dx.doi.org/10.1161/01.CIR.87.3.893.
3. Przyklenk K. Efficacy of cardioprotective ‘conditioning’ strategies in
aging and diabetic cohorts: the co-morbidity conundrum. Drugs Aging.
2011;28(5):331-43, http://dx.doi.org/10.2165/11587190-000000000-00000.
4. Przyklenk K, Darling CE, Dickson EW, Whittaker P. Cardioprotection
‘outside the box’--the evolving paradigm of remote preconditioning.
Basic Res Cardiol. 2003;98(3):149-57.
5. Przyklenk K, Frelinger AL 3rd, Linden MD, Whittaker P, Li Y, Barnard
MR, Adams J, Morgan M, Al-Shamma H, Michelson AD. Targeted
inhibition of the serotonin 5HT2A receptor improves coronary patency in
an in vivo model of recurrent thrombosis. J Thromb Haemost.
2010;8(2):331-40, http://dx.doi.org/10.1111/j.1538-7836.2009.03693.x.
6. Przyklenk K, Heusch G. Late preconditioning against myocardial
stunning. Does aspirin close the ‘‘second window’’ of endogenous
cardioprotection? J Am Coll Cardiol. 2003;41(7):1195-7, http://dx.doi.
org/10.1016/S0735-1097(03)00087-1.
7. Przyklenk K, Li G, Simkhovich BZ, Kloner RA. Mechanisms of
myocardial ischemic preconditioning are age related: PKC-epsilon does
not play a requisite role in old rabbits. J Appl Physiol. 2003;95(6):2563-9.
8. Przyklenk K, Li G, Whittaker P. No loss in the in vivo efficacy of ischemic
preconditioning in middle-aged and old rabbits. J Am Coll Cardiol.
2001;38(6):1741-7, http://dx.doi.org/10.1016/S0735-1097(01)01603-5.
9. Przyklenk K, Maynard M, Darling CE, Whittaker P. Pretreatment with
D-myo-inositol trisphosphate reduces infarct size in rabbit hearts: role of
inositol trisphosphate receptors and gap junctions in triggering protec-
tion. J Pharmacol Exp Ther. 2005;314(3):1386-92, http://dx.doi.org/10.
1124/jpet.105.087742.
10. Przyklenk K, Maynard M, Darling CE, Whittaker P. Aging mouse hearts
are refractory to infarct size reduction with post-conditioning. J Am Coll
Cardiol. 2008;51(14):1393-8, http://dx.doi.org/10.1016/j.jacc.2007.11.070.
11. Przyklenk K, Maynard M, Greiner DL, Whittaker P. Cardioprotection
with postconditioning: loss of efficacy in murine models of type-2 and
type-1 diabetes. Antioxid Redox Signal. 2011;14(5):781-90, http://dx.doi.
org/10.1089/ars.2010.3343.
12. Przyklenk K, Maynard M, Whittaker P. First molecular evidence that
inositol trisphosphate signaling contributes to infarct size reduction with
preconditioning. Am J Physiol Heart Circ Physiol. 2006;291(4):H2008-12,
http://dx.doi.org/10.1152/ajpheart.00313.2006.
13. Przyklenk K, Maynard M, Whittaker P. Reduction of infarct size with D-
myo-inositol trisphosphate: role of PI3-kinase and mitochondrial K(ATP)
channels. Am J Physiol Heart Circ Physiol. 2006;290(2):H830-6.
14. Przyklenk K, Undyala VV, Wider J, Sala-Mercado JA, Gottlieb RA,
Mentzer RM Jr. Acute induction of autophagy as a novel strategy for
cardioprotection: getting to the heart of the matter. Autophagy.
2011;7(4):432-3, http://dx.doi.org/10.4161/auto.7.4.14395.
Ischemic preconditioning in claudication
Saes GF et al.
CLINICS 2013;68(4):495-499
498
15. Przyklenk K, Whittaker P. In vitro platelet responsiveness to adenosine-
mediated ‘‘preconditioning’’ is age-dependent. J Thromb Thrombolysis.
2005;19(1):5-10.
16. Przyklenk K, Whittaker P. Cardioprotection with adenosine: ‘a riddle
wrapped in a mystery’. Br J Pharmacol. 2005;145(6):699-700.
17. Przyklenk K, Whittaker P. Adaptation of a photochemical method to
initiate recurrent platelet-mediated thrombosis in small animals. Lasers
Med Sci. 2007;22(1):42-5, http://dx.doi.org/10.1007/s10103-006-0410-1.
18. Przyklenk K, Whittaker P. Cardioprotection via adaptation to hypoxia:
expanding the timeline and targets? Basic Res Cardiol. 2011;106(3):325-8,
http://dx.doi.org/10.1007/s00395-011-0169-9.
19. Nakano A, Heusch G, Cohen MV, Downey JM. Preconditioning one
myocardial region does not necessarily precondition the whole rabbit
heart. Basic Res Cardiol. 2002;97(1):35-9, http://dx.doi.org/10.1007/
s395-002-8385-3.
20. McClanahan TB, Nao BS, Wolke LJ, Martin BJ, Mezt TE. Brief renal
occlusion and reperfusion reduces myocardial infart size in rabbits.
FASEB J. 1993;7:A18.
21. Gho BC, Schoemaker RG, van den Doel MA, Duncker DJ, Verdouw PD.
Myocardial protection by brief ischemiain noncardiac tissue. Circulation.
1996;94(9):2193-200, http://dx.doi.org/10.1161/01.CIR.94.9.2193.
22. Kharbanda RK, Mortensen UM, White PA, Kristiansen SB, Schmidt MR,
Hoschtitzky JA, et al. Transient limb ischemia induces remote ischemic
preconditioning in vivo. Circulation. 2002;106(23):2881-3, http://dx.doi.
org/10.1161/01.CIR.0000043806.51912.9B.
23. Ates¸ E, Genc¸ E, Erkasap N, Erkasap S, Akman S, Firat P, et al. Renal
protection by brief liver ischemia in rats. Transplantation. 2002;74(9):1247-
51, http://dx.doi.org/10.1097/00007890-200211150-00009.
24. Mallick IH, Yang W, Winslet MC, Seifalian AM. Ischaemic precondition-
ing improves microvascular perfusion and oxygenation following
reperfusion injury of the intestine. Br J Surg. 2005;92(9):1169-76.
25. Gurusamy KS, Gonzalez HD, Davidson BR. Current protective strategies
in liver surgery. World J Gastroenterol. 2010;16(48):6098-6103.
26. Tapuria N, Kumar Y, Habib MM, Abu Amara M, Seifalian AM,
Davidson BR. Remote ischemic preconditioning: a novel protective
method from ischemia reperfusion injury--a review. J Surg Res.
2008;150(2):304-30, http://dx.doi.org/10.1016/j.jss.2007.12.747.
27. Stewart KJ, Hiatt WR, Regensteiner JG, Hirsch AT. Exercise training for
claudication. N Engl J Med. 2002;347(24):1941-51.
28. Wolosker N, Nakano L, Rosoky RA, Puech-Leao P. Evaluation of
walking capacity over time in 500 patients with intermittent claudication
who underwent clinical treatment. Arch Intern Med. 2003;163(19):2296-
300, http://dx.doi.org/10.1001/archinte.163.19.2296.
29. Dickson EW, Reinhardt CP, Renzi FP, Becker RC, Porcaro WA, Heard
SO. Ischemic preconditioning may be transferable via whole blood
transfusion: preliminary evidence. J Thromb Thrombolysis. 1999;
8(2):123-9, http://dx.doi.org/10.1023/A:1008911101951.
30. Birnbaum Y, Hale SL, Kloner RA. Ischemic preconditioning at a distance:
reduction of myocardial infarct size by partial reduction of blood supply
combined with rapid stimulation of the gastrocnemius muscle in the
rabbit. Circulation. 1997;96(5):1641-6, http://dx.doi.org/10.1161/01.CIR.
96.5.1641.
31. Takaoka A, Nakae I, Mitsunami K, Yabe T, Morikawa S, Inubushi T, et al.
Renal ischemia/reperfusion remotely improves myocardial energy
metabolism during myocardial ischemia via adenosine receptors in
rabbits: effects of ‘‘remote preconditioning’’. J Am Coll Cardiol.
1999;33(2):556-64, http://dx.doi.org/10.1016/S0735-1097(98)00559-2.
32. Patel HH, Moore J, Hsu AK, Gross GJ. Cardioprotection at a distance:
mesenteric artery occlusion protects the myocardium via an opioid
sensitive mechanism. J Mol Cell Cardiol. 2002;34(10):1317-23, http://dx.
doi.org/10.1006/jmcc.2002.2072.
33. Harkin DW, Barros D’Sa AA, McCallion K, Hoper M, Campbell FC.
Ischemic preconditioning before lower limb ischemia–reperfusion
protects against acute lung injury. J Vasc Surg. 2002;35(6):1264-73,
http://dx.doi.org/10.1067/mva.2002.121981.
34. Lai IR, Chang KJ, Chen CF, Tsai HW. Transient limb ischemia induces
remote preconditioning in liver among rats: the protective role of heme
oxygenase-1. Transplantation. 2006;81(9):1311-7, http://dx.doi.org/10.
1097/01.tp.0000203555.14546.63.
35. Addison PD, Neligan PC, Ashrafpour H, Khan A, Zhong A, Moses M,
et al. Noninvasive remote ischemic preconditioning for global protection
of skeletal muscle against infarction. Am J Physiol Heart Circ Physiol.
2003;285(4):H1435-43.
36. Loukogeorgakis SP, Panagiotidou AT, Broadhead MW, Donald A,
Deanfield JE, MacAllister RJ. Remote ischemic preconditioning provides
early and late protection against endothelial ischemia-reperfusion injury
in humans: role of the autonomic nervous system. J Am Coll Cardiol.
2005;46(3):450-6, http://dx.doi.org/10.1016/j.jacc.2005.04.044.
37. Loukogeorgakis SP, Williams R, Panagiotidou AT, Kolvekar SK, Donald
A, Cole TJ, et al. Transient limb ischemia induces remote preconditioning
and remote postconditioning in humans by a K(ATP)-channel dependent
mechanism. Circulation. 2007;116(12):1386-95, http://dx.doi.org/10.
1161/CIRCULATIONAHA.106.653782.
38. Venugopal V, Hausenloy DJ, Ludman A, Di Salvo C, Kolvekar S, Yap J,
et al. Remote ischaemic preconditioning reduces myocardial injury in
patients undergoing cardiac surgery with cold-blood cardioplegia: a
randomised controlled trial. Heart. 2009;95(19):1567-71, http://dx.doi.
org/10.1136/hrt.2008.155770.
39. Thielmann M, Kottenberg E, Boengler K, Raffelsieper C, Neuhaeuser M,
Peters J, et al. Remote ischemic preconditioning reduces myocardial injury
after coronary artery bypass surgery with crystalloid cardioplegic arrest.
Basic Res Cardiol. 2010;105(5):657-64, http://dx.doi.org/10.1007/s00395-
010-0104-5.
40. Gurusamy KS, Kumar Y, Pamecha V, Sharma D, Davidson BR. Ischaemic
pre-conditioning for elective liver resections performed under vascular
occlusion. Cochrane Database Syst Rev. 2009;(1):CD007629.
41. Eng J. Sample size estimation: how many individuals should be studied?
Radiology. 2003;227(2):309-13, http://dx.doi.org/10.1148/radiol.227201
2051.
CLINICS 2013;68(4):495-499 Ischemic preconditioning in claudication
Saes GF et al.
499
